Wuhan Kaideweisi Biotechnology Co., Ltd, a specialist in gynecologic oncology in China, has reportedly raised close to RMB 200 million (USD 27.5 million) via a Series B financing round. The round was led by Fir Health Capital with a contribution of RMB 50 million (USD 6.9 million), and was also supported by Wuhan Hi-Tech Holding, Hongtai Group, Hubei Science Technology Investment, and Chuchuang Investment Group. The funds raised will be allocated towards the clinical development and market expansion of the company’s products within the gynecologic oncology diagnosis and treatment sector.
In-House IVD Kits and Their Impact on Gynecologic Cancer Diagnosis
Kaideweisi Bio boasts two in-house developed in vitro diagnostic (IVD) kits that have been granted fast-track statuses in China. These kits are expected to significantly enhance the rapid screening and precision diagnosis and treatment of gynecological tumors, including endometrial cancer and cervical cancer, as well as their precancerous lesions. The availability of such diagnostic tools is crucial for improving patient outcomes in the field of gynecologic oncology.
Oncolytics and HPV Therapeutic Vaccine Development
In addition to its diagnostic offerings, Kaideweisi Bio is actively developing an oncolytic virus product and an HPV therapeutic vaccine. The oncolytic virus product has received clearance for a Phase I study, marking a significant step forward in the company’s efforts to contribute to the treatment of gynecologic cancers.-Fineline Info & Tech
